Article: Finding a (biomarker) needle in the haystack
Posted: 30 April 2021 | Olink | No comments yet
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
In a study published in neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This cutting-edge approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation of the transthyretin protein is a rare, adult-onset disease characterised by the accumulation of amyloid fibrils throughout the body, leading to progressive debilitation and death.
Related content from this organisation
Related topics
Antibodies, Assays, Biomarkers, Clinical Trials, Disease Research, DNA, Protein, Proteomics, Screening, Targets
Related organisations
Olink
